Effect of dopamine agonists on fatigue and somnolence in Parkinson's disease

Dopamine agonists are becoming increasingly important in the treatment of early and advanced symptoms of Parkinson disease (PD). Although dopamine agonists are known to increase somnolence, their effect on fatigue and the relationship between fatigue and somnolence have not been investigated thoroug...

Full description

Saved in:
Bibliographic Details
Published in:Movement disorders Vol. 21; no. 8; pp. 1257 - 1261
Main Authors: Oved, Daniel, Ziv, Ilan, Treves, Therese A, Paleacu, Diana, Melamed, Eldad, Djaldetti, Ruth
Format: Journal Article
Language:English
Published: Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.08.2006
Wiley
Subjects:
Aged
Biological and medical sciences
Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases
Depression
Dopamine Agents - pharmacology
dopamine agonists
Fatigue
Female
Functional Laterality
Headache. Facial pains. Syncopes. Epilepsia. Intracranial hypertension. Brain oedema. Cerebral palsy
Humans
Male
Medical sciences
Middle Aged
Nervous system (semeiology, syndromes)
Neurology
Parkinson Disease - physiopathology
Parkinson Disease - psychology
Parkinson's disease
Parkinsons Disease
Psychological Tests
Sleep - drug effects
somnolence
somnolence, Parkinson's disease
Surveys and Questionnaires
Somnolence
Nervous system diseases
Parkinson's disease
Central nervous system disease
Dopamine agonist
Parkinson disease
Fatigue
Degenerative disease
dopamine agonists; fatigue; somnolence
Cerebral disorder
Extrapyramidal syndrome
ISSN:0885-3185, 1531-8257
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Dopamine agonists are becoming increasingly important in the treatment of early and advanced symptoms of Parkinson disease (PD). Although dopamine agonists are known to increase somnolence, their effect on fatigue and the relationship between fatigue and somnolence have not been investigated thoroughly. The objective of this study is to quantitatively measure fatigue in patients with PD treated with dopamine agonists and to correlate fatigue with somnolence. Fifteen patients with PD (mean age, 60.6 ± 9.7 years; mean disease duration, 4.1 ± 1.9 years) underwent a continuous (30‐second) motor task using four muscle groups before and after 3 months of treatment with dopamine agonists. A fatigue index, defined as the decay of maximal force during continuous exercise, was calculated. Findings were compared with 15 healthy, age‐matched control subjects. Patients also completed the Multidimensional Fatigue Inventory (MFI), the Epworth Sleepiness Scale (ESS), and the Hamilton Depression Scale at the same time points. Mean fatigue index (FI) before treatment was significantly higher in PD patients than controls (31.37% ± 3.81% vs. 23.39% ± 3.03%, P < 0.001). There was no significant between‐group difference after 3 months of treatment. There was no difference in FI of the more affected side before and after treatment (33.33% ± 6.18% vs. 34.08% ± 5.43%, P > 0.1). No significant change in MFI scores were noted after treatment, although scores on the ESS increased significantly (6.6 ± 2.63 vs. 11.7 ± 5.16; P < 0.05). Fatigue is prevalent in patients with PD but is not influenced by dopamine agonists. Somnolence cannot be attributed to the increase in fatigability and apparently involves a different mechanism. © 2006 Movement Disorder Society
Bibliography:ArticleID:MDS20929
National Parkinson's Foundation, USA
Alan and Norma Aufzien Chair for Research in Parkinson's Disease
Sackler School of Medicine, Tel Aviv University
ark:/67375/WNG-L9DLDKTN-T
istex:3D2024886689A4FFEFC2A1653A88BC5959151454
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0885-3185
1531-8257
DOI:10.1002/mds.20929